SciClone to receive $8 million from Schering Plough to settle Zadaxin dispute

By Angela McDaniels

Seattle, April 3 - SciClone Pharmaceuticals Inc. said it has reached a settlement in its dispute with Schering Plough KK concerning Schering Plough's management and conduct of clinical trials in Japan with hepatitis B drug Zadaxin, SciClone's lead compound.

Under this resolution, SciClone will receive $8 million from Schering Plough.

"Moving forward at SciClone, we plan to consider the option of pursuing further clinical development in Japan with Zadaxin, although our immediate focus for Zadaxin remains on the pursuit of regulatory approvals in the United States and Europe," president and chief executive officer Ira Lawrence said in a release.

SciClone is a biopharmaceutical company based in San Mateo, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.